Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1079]

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease...

Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA

$Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control ( Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA )$

QoL outcomes are inconsistently reported in contemporary phase III...

Dr Shreyas Kalantri - University of Louisville, Louisville

QoL outcomes are inconsistently reported in contemporary phase III genitourinary cancer trials ( Dr Shreyas Kalantri - University of Louisville, Louisville )

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS...

Dr Aly-Khan Lalani - McMaster University, Hamilton, Canada

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS benefit but is safe ( Dr Aly-Khan Lalani - McMaster University, Hamilton, Canada )

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves...

Prof Steffen Rausch - University of Tübingen, Tübingen, Germany

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC ( Prof Steffen Rausch - University of Tübingen, Tübingen, Germany )

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in...

Dr Anna Wilkins - The Institute of Cancer Research, London, UK

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer ( Dr Anna Wilkins - The Institute of Cancer Research, London, UK )

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows...

Dr Karie Runcie - Columbia University, New York, USA

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC ( Dr Karie Runcie - Columbia University, New York, USA )

ASCO GU 2026: Updates in renal cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in renal cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez...

ASCO GU 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez and Dr Guillermo de Velasco )

More from ecancer